In the Media

September 21, 2021

Growing interest in the pharmaceutical development of non-intoxicating cannabinoids

Shadd Dales of The Dales Report asks InMed CEO, Eric A. Adams, about the growing interest in the pharmaceutical development of non-intoxicating cannabinoids.

Read the article and watch the full video at The Dales Report.

Source: The Dales Report

Share this post

Latest Articles

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,

December 11, 2024

Study on Anti-Inflammation by Modulation of Endocannabinoid System

A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.

December 10, 2024

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

September 4, 2024